StockNews.com began coverage on shares of 22nd Century Group (NASDAQ:XXII – Free Report) in a research note published on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
22nd Century Group Price Performance
Shares of XXII opened at $0.09 on Wednesday. 22nd Century Group has a fifty-two week low of $0.09 and a fifty-two week high of $5.69. The firm’s 50-day simple moving average is $0.18 and its two-hundred day simple moving average is $0.61. The stock has a market cap of $4.27 million, a PE ratio of 0.00 and a beta of 1.45. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.67 and a current ratio of 1.09.
22nd Century Group (NASDAQ:XXII – Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.54) EPS for the quarter. 22nd Century Group had a negative return on equity of 380.39% and a negative net margin of 144.09%. The company had revenue of $5.95 million during the quarter.
Institutional Inflows and Outflows
About 22nd Century Group
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
Featured Stories
- Five stocks we like better than 22nd Century Group
- What Makes a Stock a Good Dividend Stock?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- What is a Death Cross in Stocks?
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- What Are Dividend Contenders? Investing in Dividend Contenders
- Time to Load Up on Home Builders?
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.